Prostrakan Share Discussion Threads

[trjones2] 14/9/2010 15:48

my 10k are not showing yet

[trjones2] 14/9/2010 13:13

im in for the bounce 47.3p directors payed over 53p safe ish bet

[grimraider] 08/9/2010 16:15

Looks like it is going to get even tougher

READING, England, September 1, 2010/PRNewswire/ -- Archimedes Pharma Ltd today announced that the European Commission has granted marketing authorization for its lead product, PecFent, an innovative fentanyl nasal spray for the treatment of breakthrough cancer pain (BTCP) in adults who are already receiving maintenance opioid therapy for chronic cancer pain.

Direct competitor in Europe to Abstral

[340r] 07/9/2010 16:51

I'm in, hopefully the departure of the CEO and the supply mess are connected. Somebody should go after losing £5m because of supply issues.

[the_doctor] 07/9/2010 12:55

All stated in posts at the time

KoKnow-it-all, you seem to have issues with accepting any good trades that others make. No doubt because it ruins your fantasy that PRM holders only ever invest in duds, none of which ever go up. I can only imagine that such desperate bitterness only comes from your own failings. A successful chap wouldnt have such issues.

[knight of no] 07/9/2010 12:52

Of course you did.

[the_doctor] 07/9/2010 12:50

'Not another one you've doomed'

I doomed it at 150p and went short.

This one that teh gang bought into at 150p?

[prambigear] 07/9/2010 11:12

Aye Knight. The_doctor knows how to pick 'em

[gopher] 07/9/2010 10:41

Agree with Bob sidian re sector as there have been few winners to counterbalance over the last few years.

The departure of the CEO alongside bad news is a sure sign that the worst may not be over. As far as I can see the company has burned through cash in anticipation of growing sales so announcements of delays is particularly difficult now the net cash balance sheet is a thing of the past. Could we be talking a dilutive share placing here?

[grimraider] 07/9/2010 09:10

Zulu, am in agreement, may be an opportunity as european sales look ok, some risk with calcium brand re recent cardio data, but otherwise looks ok.

[trjones2] 07/9/2010 09:08

picked up 10000 at 49.9, fingers crossed

[zulu002] 07/9/2010 09:05

If you read what I said, it was worth keeping an eye on as a buy in the medium to long term and that the lack of buying was a tell tale sign - it's a leaky ship. I sold out back then, but will be keeping an eye out during this drop, a drop can be a buying opportunity if it reaches a price that appeals and they don't completely mess up.

[knight of no] 07/9/2010 08:58

Oh good grief. Not another one you've doomed.

[the_doctor] 07/9/2010 08:49

Wow, didnt expect it to drop that much.

IMO there's a high chance that the FDA will issue a complete response letter for Abstral, so there may be more bad news to come

I could never understand those buying at 150p. With all of the debt, this was so overpriced.


- when did Bayer drop Tostran, think I missed or forgot that.

[bobsidian] 07/9/2010 08:45

As sectors go, it is such a minefield.

The "casualties" in this sector seem to be on the increase. ASM, AZM and SKP come to mind.

At least PSK is income generating though the extent of that ability seems to be called into question if only in the near term.

The sudden departure of the CEO will doubtless raise questions requiring of further clarification.

[jdung] 07/9/2010 08:44

now share price is 49-50p.

maybe support at this price.

waiting for city boy big size trade..., then will go up..

[grimraider] 07/9/2010 08:39

Well Zulu, what is the "positive" in the news re production/FDA delays and CEO resignation?

[bordersboy] 07/9/2010 08:11

big fall this morning.

[ricartonl] 20/8/2010 02:26

MCap £150M
Debt £30M?

Am I crazy to think the share price is still a little high? Profits of £10M+ with growth wouldbe fair at this level surely

[zulu002] 20/8/2010 01:14

business.scotsman.com

ProStrakan sets its sights on £64m sales of latest drug patch

Published Date: 20 August 2010
By PETER RANSCOMBE
PROSTRAKAN, the Borders-based specialist drugs company, is targeting sales of up to $100 million (£64m) in the United States for an anti-vomiting patch it hopes to launch before the end of the year.

But the American debut of Abstral, which is already on sale in Europe, was delayed after the US Food & Drug Administration extended the medicine's review period by three months.

Chief executive Dr Wilson Totten said he was disappointed that the FDA
had extended the review but added he was not surprised because new safety measures are being introduced for all strong opiates.

He told The Scotsman: "I would have loved for it to be approved early but I think we'll still have a positive outcome in the coming months,

"In Europe, it's sold extremely well, with sales expected to reach $20m. In the US, it could be between $50m and $100m. It's a very significant opportunity for us."

His comments came as Pro Strakan yesterday unveiled its maiden interim profit, with earnings before interest, tax, depreciation and amortisation (Ebitda) reaching £1.2m, compared with a loss of £4.3m in the first half of last year. The company said the swing into profit had been triggered by growing revenues - up 23 per cent to £45.4m - and tight controls on costs.

Chief financial officer Allan Watson said: "We've used a bit of good old-fashioned Scottish house-keeping to keep costs down.

"But we've still spent more on our sales force than last year, putting representatives in hospitals to drive sales of Abstral."

Watson noted analysts' predictions that ProStrakan may turn a pre-tax profit next year and said that was the goal towards which the firm was working.

Interim pre-tax losses narrowed from £9.4m to £2.7m.

Analysts at KBC Peel Hunt said ProStrakan's "financial performance has turned a corner" and reiterated their "buy" rating.

[grimraider] 19/8/2010 16:49

Zulu, I also note you made no mention of the manufacturing problem with Sancuso nor the fact that Bayer has also handed back rights to Tostran

[grimraider] 19/8/2010 14:43

Yes Zulu, I am consistently negative as with the exception of a brief period (the 150 level you refer to) this share has consistently been below target (under achieving on SP), with the product range it should have taken of by now - what is holding the share price and sales back?

[zulu002] 19/8/2010 14:07

Yes, not enough volume running up to H1 reporting is usually a tell tale sign. One to keep an eye on in the medium to long term.

Grim - whether the news is positive or negative you are constantly negative, and for that reason I am wary of your posts. I made a substantial amount of money on this share running up to 150, I recall your negative posts during that period & wisely ignored them.

[brucie5] 19/8/2010 12:33

Well, I've temporarily pulled the plug on these, for a better short term opportunity. Will continue to watch, and leave the analysis to better minds.

[grimraider] 19/8/2010 12:11

Yes Zulu, but not as good as needed to drive up SP, hence back down! CEO needs to do more to justify expenditure on himself and needs to get a grip on US market to see real growth in sales.